Cell Therapeutics (CTIC +9.9%) shares spike after the company reports its Pixuvri cancer drug is...

Cell Therapeutics (CTIC +9.9%) shares spike after the company reports its Pixuvri cancer drug is approved in the EU as monotherapy to treat adults with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Pixuvri is the first approved treatment in the EU in this patient setting.

From other sites
Comments (5)
  • rucinx
    , contributor
    Comments (2) | Send Message
    Finally the green lights for CTIC are on for changing all the scenario of the company to an upside return. This is an excellent achievement on the company portofolio,.
    10 May 2012, 06:30 PM Reply Like
  • grateful908
    , contributor
    Comments (181) | Send Message
    Knowing CTIC history, they'll probably sell 300 million shares at a discount to an institutional investor tomorow!!!! RUN, RUN, from this stock....;
    10 May 2012, 09:09 PM Reply Like
  • Akber
    , contributor
    Comments (63) | Send Message
    I think they do not need any more funding due to the fact they don't have any debt and the Pix has been approved in the EU which will give CTIC enough cash. I think CTIC will become Cash Cow.
    11 May 2012, 07:51 AM Reply Like
  • Akber
    , contributor
    Comments (63) | Send Message
    Hold on to the shares it will hit $50.00 with in one year as per an analyst. At the company's conference call they said it will cost Between $35000 - $ 60000 per treatment and there are thousands of patients. There are 35M shares at short interest. I think ctic will file for approval in the U.S.A soon.
    11 May 2012, 07:48 AM Reply Like
  • jack789
    , contributor
    Comments (151) | Send Message
    The company's history has been a long, long one of consistently devaluing existing shareholder's investment by diluting the stock, reverse stock splits, and paying for the CEO's high flying life style. I'd be careful. Grateful908's comment is probably right on target.
    27 Aug 2012, 12:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs